Company Filing History:
1 out of 260 
1 out of 16 Years Active: 2022
Title: Innovator Spotlight: Jun Hong Jeong
Introduction: Jun Hong Jeong, located in Yongin-si, South Korea, is a notable inventor recognized for his contributions to cancer treatment through innovative biomedical research. His pioneering work has led to the development of an anti-CD3 antibody, offering new avenues for effective cancer interventions.
Latest Patents: Jun Hong Jeong holds a patent for an "Anti-CD3 antibody and pharmaceutical composition for cancer treatment comprising same." This invention focuses on an antibody that exhibits high affinity and specificity for CD3, marking a significant advancement in the fight against cancer. The potential applications of this invention could lead to improved methods for cancer prevention and treatment.
Career Highlights: Throughout his career, Jun Hong Jeong has been associated with distinguished organizations like The Green Cross Corporation and the Mogam Institute for Biomedical Research. His expertise and dedication to biomedical research have made a lasting impact in the field of cancer therapeutics.
Collaborations: Jun Hong Jeong has collaborated with esteemed colleagues such as Ki Su Kim and Ae Rin Yoon, contributing to a collective effort in advancing cancer treatment methodologies. These partnerships highlight the collaborative nature of innovation in biomedical research.
Conclusion: Jun Hong Jeong exemplifies the spirit of innovation in the field of cancer treatment. His patent for an anti-CD3 antibody not only reflects his pioneering mindset but also promises to enhance therapeutic options for cancer patients. With a strong background in biomedical research and strategic collaborations, Jun Hong Jeong continues to contribute significantly to the field, paving the way for future innovations.